MA46672A - Immunoglobulines et utilisations de celles-ci - Google Patents

Immunoglobulines et utilisations de celles-ci

Info

Publication number
MA46672A
MA46672A MA046672A MA46672A MA46672A MA 46672 A MA46672 A MA 46672A MA 046672 A MA046672 A MA 046672A MA 46672 A MA46672 A MA 46672A MA 46672 A MA46672 A MA 46672A
Authority
MA
Morocco
Prior art keywords
immunoglobulins
Prior art date
Application number
MA046672A
Other languages
English (en)
Inventor
Mark Macielag
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62020814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46672A publication Critical patent/MA46672A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA046672A 2016-10-27 2017-10-26 Immunoglobulines et utilisations de celles-ci MA46672A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413613P 2016-10-27 2016-10-27
US201662413586P 2016-10-27 2016-10-27

Publications (1)

Publication Number Publication Date
MA46672A true MA46672A (fr) 2019-09-04

Family

ID=62020814

Family Applications (3)

Application Number Title Priority Date Filing Date
MA046718A MA46718A (fr) 2016-10-27 2017-10-26 Composés peptidiques cycliques tyrosine-tyrosine à titre de modulateurs des récepteurs du neuropeptide y
MA46665A MA46665B1 (fr) 2016-10-27 2017-10-26 Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA046672A MA46672A (fr) 2016-10-27 2017-10-26 Immunoglobulines et utilisations de celles-ci

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA046718A MA46718A (fr) 2016-10-27 2017-10-26 Composés peptidiques cycliques tyrosine-tyrosine à titre de modulateurs des récepteurs du neuropeptide y
MA46665A MA46665B1 (fr) 2016-10-27 2017-10-26 Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y

Country Status (40)

Country Link
US (15) US10968264B2 (fr)
EP (5) EP3534928A4 (fr)
JP (8) JP7231539B2 (fr)
KR (6) KR102653376B1 (fr)
CN (4) CN110099692B (fr)
AU (6) AU2017348172B2 (fr)
BR (3) BR112019008500A2 (fr)
CA (3) CA3041672A1 (fr)
CL (3) CL2019001110A1 (fr)
CO (3) CO2019003938A2 (fr)
CR (3) CR20190210A (fr)
CY (1) CY1124732T1 (fr)
DK (1) DK3532486T3 (fr)
DO (3) DOP2019000107A (fr)
EC (3) ECSP19029995A (fr)
ES (2) ES3025907T3 (fr)
HR (1) HRP20211626T1 (fr)
HU (1) HUE056442T2 (fr)
IL (6) IL266204B2 (fr)
JO (3) JOP20190097A1 (fr)
LT (1) LT3532486T (fr)
MA (3) MA46718A (fr)
MD (1) MD3532486T2 (fr)
MX (6) MX2019004955A (fr)
MY (2) MY199666A (fr)
NI (2) NI201900044A (fr)
NZ (1) NZ752396A (fr)
PE (3) PE20191079A1 (fr)
PH (3) PH12019500723A1 (fr)
PL (1) PL3532486T3 (fr)
PT (1) PT3532486T (fr)
RS (1) RS62677B1 (fr)
SA (3) SA519401642B1 (fr)
SG (4) SG10202107777XA (fr)
SI (1) SI3532486T1 (fr)
SM (1) SMT202100647T1 (fr)
TW (4) TW202304972A (fr)
UY (3) UY37457A (fr)
WO (3) WO2018081367A1 (fr)
ZA (1) ZA202200648B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083658B1 (fr) 2013-12-18 2019-05-08 President and Fellows of Harvard College Détection de bacteries gram positif à l'aide de crp
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TWI847981B (zh) 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2020188510A2 (fr) * 2019-03-19 2020-09-24 Enzene Biosciences Limited Procédé de préparation d'agonistes du récepteur du peptide-1 de type glucagon (glp-1) et de leurs analogues
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
JPWO2020262590A1 (fr) * 2019-06-28 2020-12-30
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
CA3163522A1 (fr) * 2019-12-04 2021-06-10 The Scripps Research Institute Agonistes du recepteur glp2 et methodes d'utilisation
CN111494606B (zh) * 2020-04-24 2021-12-14 广州医科大学 神经肽y的新应用
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
US20240099965A1 (en) * 2021-02-03 2024-03-28 Sun Pharmaceutical Industries Limited Oxytocin ready to infuse dosage form
CN115073556A (zh) * 2021-03-12 2022-09-20 上海天慈生命科学发展有限公司 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用
US20230015478A1 (en) * 2021-06-14 2023-01-19 Resolute Bio, Inc. Glp-1 receptor agonists having improved pharmacological and drug delivery properties
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023097363A1 (fr) * 2021-11-30 2023-06-08 Garvan Institute Of Medical Research Protéines de liaison améliorées et leurs utilisations
CN115028551B (zh) * 2022-07-15 2024-01-05 成都普康生物科技有限公司 一种叠氮-九甘醇-丙酸的制备方法
CN116098987A (zh) * 2023-02-09 2023-05-12 华东医院 甘丙肽在制备治疗非酒精性脂肪性肝病药物中的用途
CN121064327A (zh) * 2024-06-03 2025-12-05 信达生物制药(苏州)有限公司 Gipr、glp1r和/或gcgr的调节剂及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2434149A1 (fr) 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US8603969B2 (en) * 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718671A2 (fr) 2004-02-23 2006-11-08 Rheoscience A/S Analogues du peptide yy
CA2559838A1 (fr) 2004-03-17 2005-09-29 7Tm Pharma A/S Agonistes selectifs du recepteur y2 utilises dans des interventions therapeutiques
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007100535A2 (fr) 2006-02-22 2007-09-07 Merck & Co., Inc. Dérivés d'oxyntomoduline
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
CA2665808A1 (fr) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Antagonistes de ccr2 pour le traitement de la fibrose
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2009033743A1 (fr) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
JP2012508014A (ja) 2008-11-04 2012-04-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｈｒ２ペプチド作動薬及びその使用
CA2741921A1 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du recepteur 2 de neuropeptide (y-2r) et leurs utilisations
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
EP2477643A1 (fr) 2009-09-18 2012-07-25 Novo Nordisk A/S Agonistes du récepteur y2 à action prolongée
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
US20130143798A1 (en) * 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
BR112013018740A2 (pt) * 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
AU2012270366C1 (en) 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
NZ739063A (en) 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
CN105007941B (zh) 2012-12-27 2019-01-25 赛诺菲 抗-lamp1抗体和抗体药物偶联物及其用途
US10259863B2 (en) 2013-01-11 2019-04-16 The California Institute For Biomedical Research Bovine fusion antibodies
UY35548A (es) 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
WO2015157595A1 (fr) 2014-04-11 2015-10-15 Medimmune, Llc Composés conjugués comprenant des anticorps à cystéine manipulée
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
MA43164A (fr) 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途

Also Published As

Publication number Publication date
JP2025102780A (ja) 2025-07-08
JP7090077B2 (ja) 2022-06-23
NI201900043A (es) 2019-10-25
BR112019008351A2 (pt) 2019-10-01
CR20190208A (es) 2019-05-27
WO2018081375A1 (fr) 2018-05-03
IL266202A (en) 2019-06-30
JP2025131599A (ja) 2025-09-09
MA46665A (fr) 2019-09-04
EP3532486A1 (fr) 2019-09-04
SA519401647B1 (ar) 2022-01-26
EP3532486B1 (fr) 2021-09-22
CN118085061A (zh) 2024-05-28
AU2022200089B2 (en) 2023-11-16
JP7724196B2 (ja) 2025-08-15
PE20191079A1 (es) 2019-08-20
US11401315B2 (en) 2022-08-02
ES3025907T3 (en) 2025-06-10
SMT202100647T1 (it) 2022-01-10
AU2017348175B2 (en) 2021-08-26
NI201900044A (es) 2019-09-09
US10640544B2 (en) 2020-05-05
SI3532486T1 (sl) 2021-12-31
CR20190209A (es) 2019-08-21
UY37455A (es) 2018-04-30
EP4574166A3 (fr) 2025-09-03
JP2020510606A (ja) 2020-04-09
CN110036022A (zh) 2019-07-19
JP2019534281A (ja) 2019-11-28
KR20230129194A (ko) 2023-09-06
PE20190916A1 (es) 2019-06-26
TWI773699B (zh) 2022-08-11
EP3988123A1 (fr) 2022-04-27
SG11201902873RA (en) 2019-05-30
DOP2019000178A (es) 2020-02-16
TW201827456A (zh) 2018-08-01
KR102653376B1 (ko) 2024-04-02
JOP20190096B1 (ar) 2023-09-17
MX2019004954A (es) 2019-06-24
KR102653381B1 (ko) 2024-04-02
US20190345214A1 (en) 2019-11-14
EP3534928A4 (fr) 2020-08-12
PT3532486T (pt) 2021-11-19
AU2017348172B2 (en) 2021-10-07
US20210163566A1 (en) 2021-06-03
RS62677B1 (sr) 2021-12-31
JOP20190096A1 (ar) 2019-04-28
AU2025201677A1 (en) 2025-03-27
MX2023014354A (es) 2023-12-15
IL266202B1 (en) 2023-05-01
WO2018081370A1 (fr) 2018-05-03
IL266204A (en) 2019-06-30
MY199666A (en) 2023-11-15
ECSP19029835A (es) 2019-05-31
EP3532092A1 (fr) 2019-09-04
CA3041672A1 (fr) 2018-05-03
JP7231539B2 (ja) 2023-03-01
US20250026803A1 (en) 2025-01-23
CA3041674A1 (fr) 2018-05-03
IL266206A (en) 2019-06-30
TWI781118B (zh) 2022-10-21
CL2019001129A1 (es) 2019-07-05
MX2024001845A (es) 2024-03-06
PH12019500723A1 (en) 2019-11-11
US20240018208A1 (en) 2024-01-18
EP3532486A4 (fr) 2020-06-24
IL301843B1 (en) 2025-09-01
MX2023005465A (es) 2023-05-22
HUE056442T2 (hu) 2022-02-28
IL266206B2 (en) 2025-01-01
IL314935A (en) 2024-10-01
ECSP19029995A (es) 2019-05-31
KR20240046621A (ko) 2024-04-09
DOP2019000106A (es) 2019-09-30
MA46718A (fr) 2019-09-11
JP2024020405A (ja) 2024-02-14
CY1124732T1 (el) 2022-07-22
US20200385439A1 (en) 2020-12-10
EP3532486B8 (fr) 2022-01-12
JP2023012467A (ja) 2023-01-25
PE20190917A1 (es) 2019-06-26
US20210206822A1 (en) 2021-07-08
US12134636B2 (en) 2024-11-05
US11732019B2 (en) 2023-08-22
CL2019001110A1 (es) 2019-07-05
NZ793477A (en) 2025-09-26
US20230365644A1 (en) 2023-11-16
KR20240046290A (ko) 2024-04-08
TW201827081A (zh) 2018-08-01
AU2017348175A1 (en) 2019-04-18
WO2018081367A1 (fr) 2018-05-03
CL2019001136A1 (es) 2019-07-05
US20180127476A1 (en) 2018-05-10
AU2017348180B2 (en) 2024-12-12
US10858413B2 (en) 2020-12-08
US10428134B2 (en) 2019-10-01
MD3532486T2 (ro) 2022-01-31
NZ752396A (en) 2025-12-19
CO2019004186A2 (es) 2019-05-10
AU2022200089A1 (en) 2022-02-03
UY37456A (es) 2018-04-30
BR112019008417A2 (pt) 2019-09-03
MX2019004952A (es) 2019-06-24
JOP20190095A1 (ar) 2019-04-28
PL3532486T3 (pl) 2022-01-31
AU2017348180A1 (en) 2019-04-18
US20180125998A1 (en) 2018-05-10
KR20190072615A (ko) 2019-06-25
TWI794189B (zh) 2023-03-01
HRP20211626T1 (hr) 2022-02-04
KR102573684B1 (ko) 2023-09-04
CR20190210A (es) 2019-05-27
US11591379B2 (en) 2023-02-28
US10961293B2 (en) 2021-03-30
CA3041046A1 (fr) 2018-05-03
EP3988123C0 (fr) 2025-02-26
IL266204B1 (en) 2024-09-01
PH12019500749A1 (en) 2019-11-11
AU2017348172A1 (en) 2019-04-18
IL301843B2 (en) 2026-01-01
EP4574166A2 (fr) 2025-06-25
IL266202B2 (en) 2023-09-01
IL314808A (en) 2024-10-01
SG10202107777XA (en) 2021-08-30
US20190367577A1 (en) 2019-12-05
CN110099692A (zh) 2019-08-06
BR112019008500A2 (pt) 2019-07-09
JOP20190097A1 (ar) 2019-04-28
EP3988123B1 (fr) 2025-02-26
PH12019500906A1 (en) 2020-01-20
US10968265B2 (en) 2021-04-06
ECSP19029942A (es) 2019-05-31
LT3532486T (lt) 2021-11-10
US10968264B2 (en) 2021-04-06
NZ752576A (en) 2025-09-26
DK3532486T3 (da) 2021-10-18
US20210094998A1 (en) 2021-04-01
US20190298849A1 (en) 2019-10-03
IL266206B1 (en) 2024-09-01
US11767354B2 (en) 2023-09-26
US20180117170A1 (en) 2018-05-03
SA519401646B1 (ar) 2021-12-26
JP2022137031A (ja) 2022-09-21
UY37457A (es) 2018-04-30
US20200283491A1 (en) 2020-09-10
EP3532092A4 (fr) 2020-07-01
DOP2019000107A (es) 2019-09-30
US20190263879A1 (en) 2019-08-29
CN109890410A (zh) 2019-06-14
EP3534928A1 (fr) 2019-09-11
JP2019534283A (ja) 2019-11-28
US10787495B2 (en) 2020-09-29
KR20190073492A (ko) 2019-06-26
TW202304972A (zh) 2023-02-01
SG11201902886SA (en) 2019-05-30
JP7387431B2 (ja) 2023-11-28
TW201829455A (zh) 2018-08-16
CO2019003938A2 (es) 2019-04-30
MY199449A (en) 2023-10-30
SG11201902879SA (en) 2019-05-30
KR102704251B1 (ko) 2024-09-06
AU2021269420B2 (en) 2023-11-23
IL301843A (en) 2023-06-01
ZA202200648B (en) 2024-02-28
SA519401642B1 (ar) 2022-03-07
ES2897480T3 (es) 2022-03-01
IL266204B2 (en) 2025-01-01
CO2019004203A2 (es) 2019-05-10
MX2019004955A (es) 2019-06-24
CN110099692B (zh) 2024-03-12
KR20190072616A (ko) 2019-06-25
MA46665B1 (fr) 2021-09-30
AU2021269420A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MA46672A (fr) Immunoglobulines et utilisations de celles-ci
IL261442A (en) Tgfb1-binding immunoglobulins and use thereof
IL258121A (en) Anti-pro/latent-myostatin antibodies and uses thereof
EP3532100A4 (fr) Anticorps anti-pd-l1 et variants
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
EP3436867A4 (fr) Suivi de visiocasque
EP3426686C0 (fr) Anticorps anti-pacap humanisés et leurs utilisations
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3571231A4 (fr) Anticorps anti-pd-1 et leurs utilisations
PL3295951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
LT3303394T (lt) Anti-ctla-4 antikūnai ir jų naudojimo būdai
IL263329B (en) Lysine conjugated immunoglobulins
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3341485A4 (fr) Production améliorée d'immunoglobulines
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
IL270969A (en) Aggrecan binding immunoglobulins
PT3645518T (pt) Síntese de omecamtiv mecarbil
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA44878A (fr) Anticorps anti-facteur bb du complément et utilisations de ceux-ci
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3672987C0 (fr) Anticorps anti-apéline et leurs utilisations